Cn /En

News Center

——

Company news

Industry news

InnoModels: iHuPBMC-OncVax Model Features

Author:

InnoModels

Release time:

2024-03-04

With the continuous development of medical science and technology, research on cancer treatment has made significant breakthroughs. The iHuPBMC-OncVax model platform of InnoModels Biotechnology has attracted widespread attention. This vaccine platform has many unique features that bring new hope for cancer treatment.
Highly personalized:
The iHuPBMC-OncVax platform is prepared using the patient's immune cells, and personalized vaccines are tailored to the patient's specific situation. This highly personalized preparation can effectively improve the therapeutic effect of the vaccine on patients.
Dual Target Strike:
The iHuPBMC-OncVax vaccine platform employs two targets, which can ** both attack tumor cells by the immune system and inhibit the growth of tumor cells. This dual-target strike strategy can effectively improve the efficacy of the vaccine.

Innovative Preparation Process:
The iHuPBMC-OncVax vaccine platform employs an innovative preparation process that combines the patient's immune cells with tumor antigens to produce a vaccine that targets the patient's specific tumor. This process ensures a high degree of vaccine personalization and improves vaccine stability.
Wide range of application:
The iHuPBMC-OncVax vaccine platform is applicable to the treatment of a wide range of cancers, such as lung cancer, breast cancer and melanoma. This wide range of applicability makes this vaccine platform have a broad market prospect.
Remarkable clinical results:
According to the results of clinical trials, iHuPBMC-OncVax vaccine platform has achieved remarkable results in the treatment of various cancers. After using this vaccine, the condition of some patients has been effectively controlled and their survival period has been significantly extended.
In conclusion, iHuPBMC-OncVax is a breakthrough cancer vaccine platform from InnoModels Biotechnology, which brings new hope for cancer treatment with its highly personalized, dual-targeted strike, innovative preparation process, broad applicability and remarkable clinical efficacy. With further research and application of this vaccine platform, it is believed that more cancer patients will benefit.

InnoModels: Characteristics of CD34+ HSC Mouse Model

InnoModels: iHuPBMC-B Platform Introduction

InnoModels: Characteristics of CD34+ HSC Mouse Model

InnoModels: iHuPBMC-B Platform Introduction

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License